Schedule

7.00-7.30 Registration

7.25-7.30 Welcome & opening remarks : Banke Agarwal

Session I

7.30-9.15 Multidisciplinary management of esophageal cancers

Moderators : Gary Ratkin and Keith Naunheim

7.30-7.45 State of the art in esophageal adenocarcinoma : Gary Falk
  • Results of screening, surveillance and prevention of esophageal adenocarcinoma in last 25 years
7.45-8.00

Role of a therapeutic endoscopist in the management of esophageal cancer : staging and palliation : Douglas Faigel
  • EUS for staging of Esophageal cancer
    • Pre-treatment staging- what information can be obtained and always be provided
    • EUS restaging after chemo-XRT: its potential benefits in treatment planning
  • Endoscopic stent placement:
    • What is the right time in course of esophageal cancer to place stents
    • Stents vs PEG for nutritional supplementation
8.00-8.15 Surgery for patients with esophageal cancer : Cameron D Wright
  • Types of surgical operations available for esophageal cancer
  •  What are the advantages and disadvantages of each operation
  • Patient selection for surgery
8.15-8.30 Advances in the management of esophageal adenocarcinoma : David Ilson
  • What are the major oncologic achievements in their management
  • How these have impacted patient survival and quality of life
8.30-9.15 Q&A and case studies
9.15-9.30 Coffee Break & Visit Exhibits

Session II

9.30-11.00 Innovations in endoscopic management

Moderators : Steven Fern and Steven Edmundowicz

9.30-9.45 Endoscopic ablation of mucinous cysts in pancreas : John DeWitt
9.45-10.00

EUS guided biliary drainage in patients with unresectable pancreatic tumors : Janak Shah
10.00-10.15 Trans-anal endoscopic microsurgery : Eric Lederman
10.15-10.30 Cryoablation for early esophageal cancers and Barrett’s esophagus : John Dumot
10.30-11.00Q&A

Session III

11.00 -12.00 Steps to minimize medical lawsuits

Moderators : Shaun Falvey and Erik Thyssen

Panelists : Andrew Schlafly and Jeff Segal

12.00-1.00 Lunch

Session IV

1.00-2.45 Management of Pancreatic cancer

Moderators : Todd Howard and Giuseppe Aliperti

1.00-1.15

Surgery for pancreatic cancer: Patient selection and pre-operative staging : David Linehan
  • Role of pre-operative tissue diagnosis
    • What is the false positive rate for malignancy when patients are operated for pancreatic cancer without tissue diagnosis
    • When during surgery does the surgeon realize that there is no cancer in patients without pancreatic cancer
  • Pre-operative staging work-up
    • Pancreatic protocol CT
    • PET scan
    • Staging laparoscopy
  • Patient selection: age, tumor size, vascular infiltration
  • Vascular reconstruction to achieve R0 resection- Is there any survival benefit
1.15-1.30 Interventional EUS in management of patients with pancreatic cancer : Michael Levy
  • Pain control with celiac plexus neurolysis
  • EUS-guided injection of chemotherapeutic agents/biologic agents for treatment of pancreatic cancer
  • Placement of fiducials for guided radiotherapy
1.30-1.45

Role of chemoradiation in management patients with pancreatic and biliary cancer : Margaret Tempero
  • Pre-operative chemoradiation- its role in respectable and borderline resectable tumors
  • Post-operative chemoradiation for pancreatic cancer. Who needs it and what does it accomplish
  • Chemoradiation for locally advanced cancers- what does it accomplish
  • Metastatic pancreatic cancer: role of palliative chemoradiation
  • Recurrent pancreatic cancer: Does chemotherapy +/- radiation improve survival/quality of life
1.45-2.00

Determinants of survival benefit after R0 resection of pancreatic cancer : Banke Agarwal
  • Influence of tumor size, peripancreatic lymp nodes, patient age and perineural tumor infiltration on survival
  • Identification of subset of patients who most benefit from R0 resection of pancreatic cancer.
2.00-2.45Q&A and case studies
2.45-3.00Coffee break

Session V

3.00-4.00 Medical ethics : case studies

Moderators : Friedrich G. Schuening and Ira Kodner

Session VI

4.00-5.30 The future of colon cancer screening

Moderators : David Cort and Timothy Brady

4.00-4.15Anticipated issues in reimbursement for screening colonoscopy : Joel Brill
  • RUC review of colonoscopy codes
  • Carve out for sedation
  • Pathology and Anesthesia
4.15-4.30


PQRI and GIQuIC and AGA Health outcomes registry: What do we need to know and how can the data so generated be leveraged for better reimbursements : Brian Jacobson
4.30-4.45Update on competing technologies for colon cancer screening : Douglas Rex
  • Virtual colonoscopy, serum markers, capsule colonoscopy, other alternate colonoscopy techniques that require lower skill levels
  • Are they going to compete with colonoscopy for colon cancer screening any time in near future
  • What advantage does colonoscopy have on these technologies and what can we do to maintain it
4.45-5.00

Cost and time efficient use of newer techniques to improve the yield of screening and surveillance colonoscopy in practice settings : Klaus Mergener
5.00-5.30Q&A and case studies
5.30 pmConference adjourned